See more : CEMEX, S.A.B. de C.V. (CX) Income Statement Analysis – Financial Results
Complete financial analysis of Sanjivani Paranteral Limited. (SANJIVIN.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sanjivani Paranteral Limited., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
You may be interested
- China National Chemical Engineering Co., Ltd (601117.SS) Income Statement Analysis – Financial Results
- Marui Group Co., Ltd. (MAURF) Income Statement Analysis – Financial Results
- Société Générale Société anonyme (SCGLF) Income Statement Analysis – Financial Results
- Shaftesbury PLC (SHB.L) Income Statement Analysis – Financial Results
- Sun-Sea Construction Corporation (5516.TWO) Income Statement Analysis – Financial Results
Sanjivani Paranteral Limited. (SANJIVIN.BO)
About Sanjivani Paranteral Limited.
Sanjivani Paranteral Ltd. engages in the provision of pharmaceutical products. Its product category include antibiotic, anti-emetic, anti-diabetic, and anti-fungal. The company was founded by Anami H. Khemka, Ashwin A. Khemka, and Somesh Khemka on October 5, 1994 and is headquartered in Mumbai, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 536.87M | 352.43M | 303.76M | 247.07M | 160.11M | 243.61M | 178.38M | 321.98M | 1.15B | 1.33B | 1.58B | 1.52B | 1.50B | 1.44B | 1.39B | 1.03B |
| Cost of Revenue | 327.99M | 218.70M | 152.39M | 166.36M | 103.91M | 165.46M | 274.59M | 302.29M | 1.14B | 1.22B | 1.41B | 1.32B | 1.31B | 1.27B | 1.22B | 925.59M |
| Gross Profit | 208.88M | 133.72M | 151.37M | 80.71M | 56.20M | 78.15M | -96.22M | 19.68M | 8.48M | 109.16M | 171.29M | 200.94M | 190.98M | 178.96M | 171.00M | 108.01M |
| Gross Profit Ratio | 38.91% | 37.94% | 49.83% | 32.67% | 35.10% | 32.08% | -53.94% | 6.11% | 0.74% | 8.22% | 10.82% | 13.24% | 12.73% | 12.39% | 12.29% | 10.45% |
| Research & Development | 646.25K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 36.13M | 6.01M | 7.20M | 3.48M | 3.98M | 4.02M | 4.48M | 9.97M | 5.34M | 3.51M | 4.41M | 4.90M | 5.28M | 40.14M | 43.10M | 18.52M |
| Selling & Marketing | 49.60M | 39.76M | 51.60M | 20.40M | 17.06M | 17.95M | 17.98M | 26.14M | 26.73M | 24.51M | 38.35M | 50.64M | 42.55M | 0.00 | 0.00 | 0.00 |
| SG&A | 85.73M | 45.78M | 58.80M | 23.88M | 21.04M | 21.97M | 22.46M | 36.12M | 32.07M | 28.02M | 42.76M | 55.54M | 47.84M | 40.14M | 43.10M | 18.52M |
| Other Expenses | 122.50M | 92.51K | 71.20K | 265.45K | 172.27K | 290.39K | 4.01M | 11.16M | 1.41M | 272.35K | 125.63K | 23.06K | 266.22K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 208.88M | 89.55M | 106.53M | 55.65M | 53.80M | 63.22M | 81.94M | 172.38M | 77.25M | 70.06M | 81.98M | 99.21M | 85.67M | 82.18M | 59.40M | 29.87M |
| Cost & Expenses | 472.40M | 308.26M | 258.93M | 222.01M | 157.71M | 228.68M | 356.53M | 474.67M | 1.22B | 1.29B | 1.49B | 1.42B | 1.39B | 1.35B | 1.28B | 955.47M |
| Interest Income | 324.25K | 73.96K | 41.54K | 166.26K | 184.63K | 7.48M | 224.07K | 1.16M | 2.00M | 10.82M | 13.10M | 6.72M | 10.25M | 8.36M | 5.17M | 2.27M |
| Interest Expense | 2.54M | 2.30M | 832.64K | 78.24K | 5.16M | 1.74M | 3.40M | 47.35M | 81.80M | 75.08M | 71.26M | 72.14M | 81.24M | 65.19M | 44.80M | 31.27M |
| Depreciation & Amortization | 9.33M | 8.88M | 8.77M | 8.60M | 10.72M | 11.71M | 11.91M | 11.96M | 13.56M | 14.14M | 9.53M | 9.89M | 9.51M | 9.49M | 8.12M | 5.26M |
| EBITDA | 86.29M | 61.91M | 59.65M | 23.98M | -1.71M | -8.42M | -517.37M | -195.44M | -47.96M | 65.62M | 120.78M | 119.98M | 127.09M | 109.98M | 115.34M | 82.12M |
| EBITDA Ratio | 16.07% | 16.13% | 18.02% | 14.19% | 8.90% | 14.23% | -92.04% | -40.89% | -4.73% | 4.78% | 7.04% | 7.92% | 8.22% | 7.36% | 8.60% | 8.10% |
| Operating Income | 64.47M | -19.53M | 32.52M | 9.11M | -16.89M | -36.53M | -533.39M | -174.59M | -149.62M | -27.75M | 30.36M | 37.96M | 32.68M | 35.30M | 62.43M | 45.78M |
| Operating Income Ratio | 12.01% | -5.54% | 10.70% | 3.69% | -10.55% | -14.99% | -299.03% | -54.22% | -12.97% | -2.09% | 1.92% | 2.50% | 2.18% | 2.44% | 4.49% | 4.43% |
| Total Other Income/Expenses | 11.25M | 1.41M | 3.95M | -10.94M | -20.49M | -37.90M | -355.57M | -89.54M | -81.15M | -67.25M | -55.77M | -58.14M | -69.17M | -54.04M | -46.76M | -30.97M |
| Income Before Tax | 75.72M | 49.44M | 48.79M | 14.12M | -18.09M | -22.96M | -533.73M | -264.13M | -149.62M | -27.75M | 30.36M | 37.96M | 32.68M | 35.30M | 62.43M | 45.78M |
| Income Before Tax Ratio | 14.10% | 14.03% | 16.06% | 5.72% | -11.30% | -9.43% | -299.22% | -82.03% | -12.97% | -2.09% | 1.92% | 2.50% | 2.18% | 2.44% | 4.49% | 4.43% |
| Income Tax Expense | 14.06M | 4.33M | 321.51K | -71.53K | -1.00M | -2.30M | -3.16M | -1.92M | -3.21M | -3.61M | 14.42M | 13.65M | 5.78M | 13.20M | 26.40M | 16.52M |
| Net Income | 61.65M | 45.12M | 48.46M | 14.19M | -17.08M | -20.67M | -530.57M | -262.20M | -146.41M | -24.14M | 15.94M | 24.31M | 26.90M | 22.10M | 36.03M | 29.26M |
| Net Income Ratio | 11.48% | 12.80% | 15.95% | 5.74% | -10.67% | -8.48% | -297.44% | -81.44% | -12.70% | -1.82% | 1.01% | 1.60% | 1.79% | 1.53% | 2.59% | 2.83% |
| EPS | 5.28 | 4.51 | 4.85 | 1.67 | -2.90 | -3.50 | -89.95 | -44.45 | -24.82 | -4.09 | 2.70 | 4.12 | 4.56 | 3.75 | 6.11 | 4.96 |
| EPS Diluted | 5.28 | 4.51 | 4.85 | 1.67 | -2.90 | -3.50 | -89.95 | -44.45 | -24.82 | -4.09 | 2.70 | 4.12 | 4.56 | 3.75 | 6.11 | 4.96 |
| Weighted Avg Shares Out | 11.68M | 10.00M | 10.00M | 8.50M | 5.90M | 5.90M | 5.90M | 5.90M | 5.90M | 5.90M | 5.90M | 5.90M | 5.90M | 5.90M | 5.90M | 5.90M |
| Weighted Avg Shares Out (Dil) | 11.68M | 10.00M | 10.00M | 8.50M | 5.90M | 5.90M | 5.90M | 5.90M | 5.90M | 5.90M | 5.90M | 5.90M | 5.90M | 5.90M | 5.90M | 5.90M |
No news found for: SANJIVIN.BO
Source: https://incomestatements.info
Category: Stock Reports